Jefferson Institute of Molecular Medicine and The Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, USA.
Rheumatology (Oxford). 2018 Oct 1;57(10):1698-1706. doi: 10.1093/rheumatology/kex404.
There is an important unmet need for clinically validated non-invasive biomarkers for SSc diagnosis, assessment of disease activity, extent of internal organ involvement, therapeutic response and prognosis. There is also an unmet need for biomarkers to accurately differentiate primary RP from recent onset RP evolving into SSc. The lack of sensitive and specific biomarkers for SSc and SSc-associated RP is a limitation for the optimal clinical management of these patients. The development of highly sensitive and specific proteomic analysis employing aptamers and the expansion in the number of proteins that can be specifically identified by aptamer proteomics have opened new horizons for biomarker discovery. Here, we review the background and rationale for aptamer proteomic analysis for the identification of novel non-invasive biomarkers for SSc and recent onset RP evolving into SSc. Large scale application of aptamer proteomic platforms for this purpose will be of substantial value for the precision and personalized medical care of SSc patients. These studies will be placed in context by comparison with proteomic biomarker studies performed for other rheumatological inflammatory and autoimmune diseases.
对于临床上经过验证的、用于 SSc 诊断、疾病活动评估、内脏器官受累程度、治疗反应和预后的非侵入性生物标志物，存在着重要的未满足的需求。此外，也需要生物标志物来准确地区分原发性硬皮病相关间质性肺病（RP）和近期发作的 RP 进展为 SSc。缺乏用于 SSc 和 SSc 相关 RP 的敏感和特异性生物标志物，限制了这些患者的最佳临床管理。采用适体的高度敏感和特异性蛋白质组学分析的发展，以及可通过适体蛋白质组学特异性识别的蛋白质数量的增加，为生物标志物的发现开辟了新的前景。在这里，我们回顾了适体蛋白质组学分析用于识别 SSc 和近期发作的 RP 进展为 SSc 的新型非侵入性生物标志物的背景和原理。为此目的大规模应用适体蛋白质组学平台将对 SSc 患者的精准和个性化医疗护理具有重要价值。这些研究将通过与其他风湿性炎症性和自身免疫性疾病进行的蛋白质组生物标志物研究进行比较，来进行阐述。
